Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance of effect, tolerance and safety of Sativex in neuropathic pain with randomised withdrawal
2004-004395-36Phase 3Completed
- Sponsor
- GW Pharmaceuticals
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cannabidiol in Neuralgia (3 arms), sponsored by GW Pharmaceuticals. Primary endpoints: Investigational medicinal product dosing and Average pain severity. Started May 2005; status: completed.
02
Drugs
cannabidiol
03
Conditions
Neuralgia
Beyond the preview
Go deeper on 2004-004395-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004395-36.